New application of the R-enantiomer of adrenergic β2 receptor agonist in the treatment of inflammatory bowel disease and extraintestinal diseases

By using optically pure R-enantiomer adrenergic β2 receptor agonists, the existing IBD treatment toxicity and adverse reactions have been solved, significantly improving the clinical symptoms and histological characteristics of IBD, providing more effective and Safe treatment options.

CN113613640BActive Publication Date: 2024-11-29谭文
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN201980073231.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-09-07
Publication Date
2024-11-29
Estimated Expiration
2039-09-07

AI Technical Summary

Technical Problem

The existing drugs for the treatment of inflammatory bowel disease (IBD) have serious adverse reactions and toxicities, and the lack of effective long-term remission treatment methods, which leads to the need for surgical treatment. The exact cause of IBD is not yet known, and the current treatment method cannot be completely Resolve the chronic and complexity of the disease.

Method used

Optical pure R-enantiomeric adrenergic β2 receptor agonists, such as R-albutamol, R-bambutol, etc., are used alone or in combination with anti-inflammatory drugs and immunosuppressants for the treatment of IBD and its Parenteral disease reduces inflammatory response by inhibiting macrophage polarization and lymphocyte activation.

Benefits of technology

Significantly improve the clinical symptoms and histological characteristics of IBD, reduce disease activity index and histological score, reduce adverse reactions, improve the safety and tolerance of treatment, and provide more effective long-term relief effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0005108471170000141
    Figure GDA0005108471170000141
  • Figure GDA0005108471170000161
    Figure GDA0005108471170000161
  • Figure GDA0005108471170000191
    Figure GDA0005108471170000191
Patent Text Reader

Abstract

The present invention discloses a novel application of optically pure adrenergic β2 receptor agonist R-enantiomers (including R-salbutamol, R-terbutaline, R-clenbuterol and R-bambuterol) for treating inflammatory bowel disease and extraintestinal diseases including skin diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to a new use of an optically pure R-enantiomer of an adrenergic β2 receptor agonist for treating inflammatory bowel disease (IBD) and extraintestinal diseases of inflammatory bowel disease. The exact cause of IBD is still unclear, but IBD is the result of a defective immune system. IBD includes Crohn's disease and ulcerative colitis, which are characterized by chronic inflammation of the gastrointestinal tract, persistent diarrhea, abdominal pain, rectal bloody stools, weight loss and fatigue. IBD is associated with extraintestinal symptoms such as liver problems, arthritis, skin symptoms and eye problems. There is currently no effective drug for the treatment of IBD. The main therapeutic drugs for controlling IBD symptoms include anti-inflammatory drugs, such as sodium 5-aminosalicylate and corticosteroids, and immunosuppressants, such as cyclosporine. Long-term use of these drugs often causes serious adverse reactions. IBD sometimes requires surgical treatment. Therefore, there is a need for a more effective and safer drug to help patients who need treatment for IBD, and the medical needs in this regard have not been met.

[0002] The present invention discloses a new use of the R-enantiomer of a chiral adrenergic β2 receptor agonist in treating IBD and an extraintestinal disease of IBD. The present invention also unexpectedly discovered that the S-enantiomer of a chiral adrenergic β2 receptor agonist can cause IBD to aggravate. Therefore, the R-enantiomer of a β2 receptor agonist is superior to its racemate in treating IBD, while avoiding the toxicity of the S-enantiomer. The present invention discloses an R-enantiomer of an adrenergic β2 receptor agonist for treating IBD and an extraintestinal disease thereof, which has less side effects than its racemic drugs and other drugs already on the market. According to the present invention, the R-enantiomer of an adrenergic receptor agonist includes a short-acting β2 agonist (SABA), an eutectic R-salbutamol and a long-acting β2 agonist (LABA), an eutectic R-bambuterol and an R-clenbuterol. The present invention also discloses the use of at least one R-enantiomer of an adrenergic beta2 receptor agonist in combination with at least one anti-inflammatory drug such as a corticosteroid and at least one immunosuppressant, or with an antibody for IBD and an S1P receptor modulator. The present invention discloses a novel R-enantiomer of an adrenergic beta2 receptor agonist for the treatment of extraintestinal manifestations of IBD, including arthritis, uveitis, rhinitis, ankylosing spondylitis, vitiligo, psoriasis, amyloidosis, eczema, acne and primary sclerosing cholangitis. Background Art

[0003] Inflammatory bowel disease (IBD) is a general term for two diseases (Crohn's disease and ulcerative colitis) characterized by chronic inflammation of the gastrointestinal tract caused by autoimmune dysfunction. Prolonged inflammation leads to gastrointestinal damage. Some common symptoms are: persistent diarrhea, abdominal pain, rectal bleeding, blood in the stool, weight loss and fatigue (Baumgart DC, & Carding SR Inflammatory bowel disease: cause and immunobiology. Lancet. 369 (9573): 1627, May 2007). Related diseases include arthritis, pyoderma gangrenosum, primary sclerosing cholangitis and non-thyroidal disease syndrome (NTIS) (Liu S, et al., "Nonthyroidal illness syndrome: is it far away from Crohn's disease?. Journal of Clinical Gastroenterology. 47 (2): 153-9. February 2013). Secondly, Crohn's disease and ulcerative colitis present with varying degrees of extraintestinal manifestations (such as liver disease, arthritis, skin symptoms and eye symptoms) (Extraintestinal manifestations of inflammatory bowel disease, Levine JS et al. Gastroenterology & hepatology Vol. &, Issue 4, 235, April 2011).

[0004] The overall prevalence of IBD is 396 per 100,000 people per year. In 2013, a total of 51,000 people died from IBD worldwide. The increase in the incidence of IBD since World War II has been linked to an increase in meat consumption worldwide, supporting the idea that animal protein intake is associated with IBD. Inflammatory bowel disease is increasing in Europe. The exact cause of IBD is unknown, but IBD is the result of a defect in the immune system. A normally functioning immune system attacks foreign organisms, such as viruses and bacteria, to protect the body. In IBD, the immune system does not respond correctly to the environment causing inflammation of the gastrointestinal tract. There also appears to be a genetic component to this.

[0005] There are several medications that treat IBD: 5-aminosalicylic acid, corticosteroids (such as prednisone), immunomodulators, and the most recently approved medications for IBD (biologics). There are also several vaccines recommended to prevent infections in people with IBD. Severe IBD patients may need surgery to remove damaged parts of the gastrointestinal tract, but advances in medical treatments mean that surgery is less common than it was decades ago. Because Crohn's disease and ulcerative colitis affect different parts of the gastrointestinal tract, the surgical approach for these two conditions is different.

[0006] Steroids, such as the glucocorticoid prednisone, are often used to control flare-ups and were once an acceptable maintenance agent. Biologic therapies for inflammatory bowel disease, particularly TNF inhibitors, are used for more severe or resistant Crohn disease and sometimes for ulcerative colitis.

[0007] Despite recent advances in treatment, there is still a need for a safe, well-tolerated, fast-acting treatment that enhances long-term remission. In addition, long-term use of drugs such as steroids can cause serious side effects. Therefore, there is an urgent need for better drug treatments for IBD that can improve efficacy, reduce adverse reactions, and reduce costs. Summary of the invention

[0008] IBD animal models are important research tools for studying the pathogenesis of IBD, providing a wide range of options for studying various factors of IBD and evaluating different treatment options. Even though no single model can represent all aspects and stages of ulcerative colitis, that is, ulcerative colitis is mainly confined to the colonic mucosa, or Crohn's disease affects the entire gastrointestinal tract through transmural inflammation (R. B. Sartor and M. Muehlbauer, "Microbial host interactions in IBD: implications for pathogenesis and therapy," Current Gastroenterology Reports, vol. 9(6), pp. 497, 2007).

[0009] The colitis model induced by dextran sodium sulfate (DSS) is a currently recognized and widely used inflammatory bowel disease model. Compared with other animal colitis models, the DSS-induced colitis model has certain advantages. For example, by changing the administration concentration of DSS, acute, chronic or recurrent models can be easily established. In addition, abnormal proliferation that often occurs in clinical human enteritis is also often seen in chronic enteritis induced by DSS. In recent years, people have reviewed the DSS-induced colitis-related carcinogenesis model. In addition, studies using different IBD therapeutic drugs to verify the DSS model have shown that the DSS-induced mouse colitis model can be converted into a relevant model of human disease (Perse M & Cerar A, Dextran sodium sulfate colitis mouse model: traps and tricks. J of Biomedicine and Biotechnology, Vol. 2012, ID 18617, Mar. 2012). The present invention adopts a DSS mouse model. In the prior art, R-salbutamol has been shown to be effective in treating asthma. It is also the main drug for treating skin diseases such as discoid lupus erythematosus. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus (Br. J. Demortol. 161(16):1365, Dec. 2009) promoted the healing of chronic wounds on the skin. However, IBD is a disease that is completely different from asthma and discoid lupus (connective tissue disease) or impaired chronic wound healing on the skin. The above clinical manifestations and histological features of colitis were significantly improved after R-salbutamol treatment. DAI was significantly improved, weight gain, diarrhea was reduced, and fecal occult blood was reduced. In pathological and histological examinations, the colorectal shortening rate was reduced after R-salbutamol treatment. Mucosal distortion or erosion was reduced. The inflammatory response of the mucosa and submucosal layer was significantly reduced. A large number of newly grown crypts appeared. The inner layer of the colonic mucosal epithelium was significantly restored. The lamina propria was intact and no obvious inflammatory infiltration was observed. Compared with DSS-induced colitis mice, the histological scores of R-salbutamol-treated colitis mice were significantly reduced. The present invention discloses that R-salbutamol can be used for preventing and treating IBD. This report is novel and cannot be predicted or inferred by those in the industry. IBD cannot usually be treated topically through the skin. IBD is a chronic disease whose pathogenesis is different from the clinical manifestations of diseases that can be treated with R-salbutamol or other β2 agonists. Whether R-salbutamol or other similar β2 agonists are used for the treatment of IBD has never been reported.

[0010] The present invention discloses that R-salbutamol can be used to prevent or treat IBD. In one embodiment, DSS is added to drinking water to induce IBD in mice for 7 days. After a few days, clinical manifestations of colitis, including weight loss, diarrhea, and increased disease activity index including fecal occult blood (FOB) (Cooper, S. et al., Clinic pathologic study of dextran sulfate sodium experimental murine colitis, Laboratory Investigation, vol. 69, no. 2, p. 238-249, 1993).

[0011] The mice were dissected and histologically identified on the 10th day. The length of the colorectum was shortened. The histological manifestations of acute colitis are reduced mucus, epithelial cell degeneration, and necrosis leading to the disappearance of epithelial cells. Accompanied by the infiltration of neutrophils and the destruction of the lamina propria and submucosa, occult inflammation (transepithelial migration of neutrophils to the mucosal epithelium), and cellulitis of the mucosa and submucosa. Both the mucosa and submucosa showed erosions, cellular inflammatory changes, and the crypts disappeared. Each of the above histological features was scored separately, added together, and collectively expressed as the "histological score" for quantitative evaluation (Cooper, S. et al., above).

[0012] The above clinical manifestations and histological features of colitis were significantly improved after R-salbutamol treatment. DAI was significantly improved. Weight gain, diarrhea and FOB were significantly reduced. In pathological and histological examinations, the colorectal shortening rate was reduced after R-salbutamol treatment. Mucosal abnormalities or erosions were reduced. The inflammatory response of the mucosa and submucosal layers was significantly alleviated. With the obvious recovery of the inner layer of the colonic mucosal epithelium, a large number of new crypts appeared. The propria was intact and no obvious inflammatory infiltration was observed. Compared with DSS-induced colitis mice, the histological scores of R-salbutamol-induced colitis mice were significantly reduced. The present invention discloses that R-salbutamol can be used to prevent and treat IBD. This report is novel.

[0013] In other embodiments, the present invention provides similar effects of other short-acting β2 agonists including R-terbutaline and long-acting β2 agonists including R-bambuterol and R-clenbuterol in preventing and treating DSS-induced IBD. The present invention discloses a novel use of the R enantiomer or R enantiomer of an adrenergic β2 agonist in preventing and treating IBD. The disclosure of the present invention is novel.

[0014] Corticosteroids are commonly used drugs for the treatment of IBD. In one embodiment, the R enantiomer adrenergic agonist provided by the present invention has a better effect than dexamethasone in improving IBD.

[0015] Most chiral adrenergic β2 agonists currently on the market are sold in the racemic form of a mixture of R and S enantiomers. It is well known that one enantiomer may sometimes be inert and not have the same biological activity as the other. However, in the current literature, the toxic effects of the S-enantiomer on IBD have not been reported. In one embodiment, S-salbutamol replaced R-salbutamol and was used in IBD mice in the same manner as R-salbutamol. Surprisingly, S-salbutamol did not show the improvement or therapeutic effect of R-salbutamol. On the contrary, S-salbutamol significantly worsened the clinical manifestations and inflammatory characteristics of mice under DSS stimulation. Compared with untreated DSS mice, DAI was significantly aggravated. In particular, FOB was significantly worse than that of untreated DSS mice. The length of the colon was further shortened than that of untreated DSS mice. Compared with untreated DSS mice, mucosal erosion, epithelial cell damage and crypt loss in DSS mice were more severe. Compared with untreated DDS mice, the inflammatory infiltration of the mucosa and submucosa, lamina propria and muscle layer of DDS mice was enhanced, and the destruction of the lamina propria was more serious. The histological score was significantly higher than that of untreated DSS mice. The present invention discloses that S-salbutamol has toxic effects on the intestine, which can further aggravate the clinical symptoms and inflammatory reactions of IBD. In addition, removing S-enantiomer salbutamol from racemic salbutamol, for example, using R-enantiomer salbutamol instead of racemic salbutamol, can reduce the toxicity and unnecessary adverse effects caused by S-enantiomer salbutamol. The disclosure of the present invention should be considered novel. The toxic effects of these S-enantiomer β2 agonists are unexpected and unpredictable.

[0016] In another embodiment, other S-enantiomers of β2 adrenergic agonists, including S-terbutaline and S-bambuterol, were used in DSS mice in the same manner as S-salbutamol. Similar toxic effects were observed. DSS mice treated with S-enantiomer β2 receptor agonists had significantly higher disease activity index (DAI) and histological scores than untreated DSS mice. The present invention discloses that S-enantiomer β2 agonists are toxic to the intestine and can further aggravate the clinical symptoms and inflammatory response of IBD. In addition, the present invention discloses a new use of R-enantiomer β2 agonists in the treatment of IBD with reduced toxicity. The present invention points out that removing the S-enantiomer from the racemate, such as replacing the racemic β2 agonist with an R-enantiomer β2 agonist, can reduce the toxicity and adverse reactions caused by the S-enantiomer. Such reports of the present invention should be considered novel. These toxicities are unexpected.

[0017] The present invention also discloses R-salbutamol for the treatment of IBD in the subacute or chronic phase. In one embodiment, as described above, DSS induces IBD, and R-salbutamol treatment is given at the same time. On the 7th day, DSS is removed and replaced with drinking water for 2 weeks. The disease activity index (DAI) of mice is regularly detected. Pathological and histological examinations were performed on mice on the 23rd day. In DSS-induced IBD mice, body weight and fecal occult blood were significantly reduced on the 14th and 22nd days, and the overall condition of colitis was very serious, although it was improved compared with the 7th day. Compared with the control group, the colon length was significantly shortened and the histological score was significantly increased. Obvious mononuclear cell infiltration, disordered crypt structure, epithelial cell degeneration, and mucosal abnormalities can be seen in DSS-induced colitis mice. Mucosal lymphocyte hyperplasia, lamina propria destruction, and sometimes transmural inflammation can be seen.

[0018] Compared with untreated DSS animals, the DAI disease activity index was significantly improved after R-bambuterol treatment. The body weight was similar to that of control normal mice; after R-salbutamol treatment, fecal occult blood in DSS mice was significantly reduced. Histological indices also improved significantly after treatment. Crypt regeneration was basically completed and arranged normally. Normally grown epithelial cells formed a complete mucosal surface. The lamina propria was intact and basically normal. There was a small amount of inflammatory infiltration in the mucosa or submucosa.

[0019] In one embodiment, similar to the above study, the difference is that the treatment starts from day 7 until day 22, instead of starting from day 1 until day 22 as above. The results are similar to the above, and R-salbutamol has a significant therapeutic effect on DSS-induced IBD mice.

[0020] The present invention discloses that R-salbutamol can be used to prevent or treat subacute or chronic IBD. This report in the present invention is novel.

[0021] In one embodiment, the present invention further discloses that R-salbutamol and other R-enantiomer β2 agonists have significant therapeutic effects in treating TNBS-induced colitis in mice (a common animal model of Crohn's disease). R-salbutamol is more effective than infliximab (IFX) in treating IBD. A male mouse colitis model was induced by rectal injection of ethanol and TNBS (trinitrobenzene sulfonic acid). Mice had severe colitis characterized by weight loss and diarrhea. Histologically, normal structures were lost, discrete epithelioid granulomas, multiple erosive lesions, a large number of lymphocyte penetrating inflammatory infiltrations, and goblet cell loss were seen. However, the condition improved significantly after oral administration of salbutamol or clenbuterol. There was no significant difference between mice treated with R-salbutamol or R-clenbuterol and normal control mice in terms of weight loss, diarrhea, and colon length. The lesions were significantly alleviated, there was little inflammatory infiltration with crypt growth, and mucosal epithelium was restored. In addition, the therapeutic effect of infliximab was similar to that of salbutamol, however, animals treated with IFX had significant submucosal fibrosis and intestinal stenosis, while animals treated with R-salbutamol and R-clenbuterol did not have this phenomenon. In addition, mice with TNBS-induced colitis developed perianal symptoms: some mice developed erythema, abscesses, and ulcers, which may lead to perianal fissures or fistulas. However, these perianal symptoms in TNBS-induced mice were significantly alleviated after treatment with R-salbutamol or R-bambuterol. In existing reports, the therapeutic effects of R-salbutamol, R-clenbuterol, and R-bambuterol on TNBS-induced Crohn's disease symptoms have never been reported.

[0022] These perianal lesions are somewhat similar to the symptoms of hemorrhoidal inflammation. In one embodiment, the present invention discloses that oral or topical administration of R-salbutamol, R-clenbuterol and R-bambuterol can significantly reduce the symptoms of hemorrhoidal inflammation. This new beta 2 agonist has never been reported for the treatment of hemorrhoidal inflammation symptoms.

[0023] In another embodiment, the invention reveals that TNBS-induced Crohn's disease has submucosal fibrosis and luminal stenosis, which may lead to surgery in IBD patients. R-salbutamol treatment can significantly reduce intestinal fibrosis and stenosis. On the other hand, infliximab treatment enhances submucosal fibrosis and luminal stenosis. These beneficial effects of R-salbutamol are novel.

[0024] In another embodiment, other R-enantiomers include short-acting β2 agonists, R-terbutaline or long-acting β2 agonists R-bambuterol and R-clenbuterol, respectively, for the above-mentioned subacute or chronic DSS mice. These drugs of R-enantiomer β2 agonists significantly improved the subacute or chronic clinical symptoms and pathological changes caused by DSS or TNBS. Compared with untreated DSS- or TNBS-induced IBD mice, the disease activity index and histological scores were significantly improved after treatment with the R-enantiomer of the β2 agonist. The present invention discloses that R-enantiomer β2 agonists can be used for the treatment of subacute or chronic IBD (including UC and Crohn's disease), and its therapeutic effect is significantly better than that of drugs already on the market. The report of this invention is novel and cannot be predicted or inferred by people in the industry.

[0025] The present invention also discloses a group of novel uses of R-enantiomer β2 agonists in preventing and treating the above-mentioned IBD and related hemorrhoidal symptoms as follows: short-acting β2 agonists: bitolterol, fenoterol, isoproterenol, oxyproterenol or methylproterenol; long-acting β2 agonists: formoterol, arformoterol, perforomist, salmeterol, kawamachiterol; and ultra-long-acting β2 agonists: abitrol, carmoterol, indacaterol, lodacaterol, vilanterol, isosuprine, maboterol and zilpaterol.

[0026] In one embodiment, S-salbutamol and S-banbuterol are used in the same manner as R-salbutamol mentioned above after DSS-induced IBD. DAI and histological scores were checked regularly within 22 days. Surprisingly, compared with R-salbutamol, S-salbutamol and S-banbuterol did not show signs of improved symptoms or therapeutic effects. On the contrary, both S-salbutamol and S-banbuterol worsened disease manifestations and inflammatory responses compared with DSS mice. Compared with untreated DSS mice, DAI was significantly worsened after S-salbutamol treatment. In particular, compared with untreated mice, mice treated with S-salbutamol and S-banbuterol had lower body weight, more severe fecal occult blood on days 14 and 22, and shorter colon length. Histologically, there were inflammatory infiltrations in the mucosa, lamina propria, submucosal layer and even muscular layer. Crypts disappeared, epithelial degeneration, and mucosal erosions. The histological scores of DSS mice treated with S-salbutamol and S-bandrol were significantly higher than those of untreated DSS mice.

[0027] The present invention discloses that, unlike the R-enantiomer, S-salbutamol and S-bambuterol are toxic, rather than beneficial, to the intestines of IBD. Treatment with S-salbutamol and S-bambuterol further aggravates the clinical symptoms and inflammatory responses of IBD. In addition, removing S-enantiomer salbutamol and S-enantiomer bambuterol from their racemic forms, such as using R-salbutamol instead of racemic salbutamol and bambuterol, can significantly reduce toxicity and adverse reactions. Therefore, the present invention discloses a new use of R-salbutamol or R-bambuterol or other R enantiomer β2 agonists for the treatment of subacute or chronic IBD to reduce adverse reactions. The report of the present invention should be considered novel and involves creative steps because these toxic effects are unexpected.

[0028] In another embodiment, other S-enantiomers of β2 adrenergic agonists, including S-terbutaline and S-clenbuterol, were used in DSS mice in the same manner as described above. Similar toxic effects were observed. The disease activity index (DAI) and histological scores of DSS mice treated with S-terbutaline and S-clenbuterol were much worse than those of untreated DSS mice. The present invention reveals that S-terbutaline and S-clenbuterol are toxic to the intestine, rather than having a therapeutic effect on the intestine like the R-enantiomer.

[0029] Therefore, the present invention discloses a new use of R-terbutaline or R-clenbuterol and other R-enantiomer β2 agonists for the treatment of subacute or chronic IBD to reduce adverse reactions. Other R-enantiomer β2 agonists according to the present invention include: R or R'R' enantiomers of short-acting β2 agonists: bitolterol, fenoterol, isoproterenol, oxiprinarin or methylproterenol, bilbuterol, procaterol, ritodrine; long-acting β2 agonists: salmeterol, tranteniterol, aformoterol, formoterol, perforomist, trantenterol; and ultra-long-acting β2 agonists: abitrol, carmoterol, indacaterol, lodacaterol, vilanterol, isosuprine, mabotrol and zilpaterol.

[0030] In one embodiment, the present invention discloses the therapeutic mechanism of R-enantiomer β2 agonists in IBD and its related symptoms, involving inhibition of macrophage polarization and inhibition of activation of intestinal innate lymphocytes, CD4 and CD8 T lymphocytes, and induction of metabolism and reorganization in these cells. On the other hand, S-enantiomer β2 agonists play the opposite role. These findings are novel and have not been reported in the prior art.

[0031] Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are common in both ulcerative colitis (UC) and Crohn's disease (CD). These manifestations can involve almost multiple organ systems, including musculoskeletal, skin, hepato-pancreatic bile duct, eyes, kidneys, and lungs. These can pose a huge challenge to physicians in treating IBD patients. The results showed that 31.4% of UC patients and 40.4% of CD patients had one of the five major manifestations, and a few patients had more than one major EIMs. Some data show that about one-third of patients will develop symptomatic primary sclerosing cholangitis (PSC) before being diagnosed with IBD. According to some small studies, 10-30% of patients with IBD-related arthritis will have arthritis symptoms before being diagnosed with IBD. (Levine et al., Extratestinal Manifestations of Inflammatory Bowel Disease. Gastroenterology & Hepatology Volume 7, Issue 4, 235 April. 2011).

[0032] Skin problems affect about 15% of patients with different types of IBD. Skin problems involve inflammatory skin diseases (ISDs), mainly including psoriasis, rosacea and atopic dermatitis (Kim et al., Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases, JAm Acad Dermatol. 2017 Jan; 76 (1)). It also includes autoimmune skin diseases such as lupus, vitiligo and alopecia areata. Skin diseases associated with IBD also include: miliaria, pyoderma gangrenosum, Sweet syndrome, bowel-associated dermatosis-arthritis syndrome (BADAS), phytoderma-pyostomy (PPV). Allergic vasculitis, acne and urticaria (Elaine K. Luo, and Ana Gotter, 10 Skin Rashes Linked to Ulcerative Colitis, Medically reviewed July 5, 2017)

[0033] The present invention discloses that the R-enantiomer of a β2 agonist can be used to treat extraintestinal manifestations of inflammatory bowel disease (EMI), including arthritis, osteoarthritis, lupus, ankylosing spondylitis, vitiligo, psoriasis, amyloidosis, erythema nodosum, pyoderma gangrenosum, primary sclerosing cholangitis, acne, eczema, urticaria, uveitis, iritis, episcleritis, scleromalacia, corneal ulcers, retinal vascular diseases, rhinitis and pulmonary inflammatory diseases.

[0034] In one embodiment, knee joint damage was also present in DSS-induced IBD mice. The articular cartilage structure was thinned and partially destroyed. Chondrocytes degenerated, decreased, and aggregated. The meniscus was damaged and lost its structural integrity. X-ray results showed that the articular cartilage layer was thinned and the bone structure was reduced. The above damage was significantly reduced in mice treated with salbutamol or bambuterol. The articular cartilage and bone structure gradually returned to normal.

[0035] The present invention provides a new use of R-salbutamol or R-bambuterol for treating IBD arthritis. In another embodiment, S-salbutamol and S-bambuterol are used in DSS-induced IBD mice, and the damage to articular cartilage and meniscus is aggravated compared with untreated DSS mice. The present invention discloses that S-salbutamol and S-bambuterol are harmful to cartilage and meniscus. In addition, the present invention discloses a new use of R-salbutamol or R-bambuterol for treating arthritis, and can reduce adverse reactions. It is known in the prior art that extraintestinal manifestations (EIMs) of IBD have a common pathogenesis. The present invention also discloses the use of R-salbutamol or R-bambuterol for treating other extraintestinal manifestations (EIMs) of the above-mentioned IBD, including arthritis, ankylosing spondylitis. Oral Crohn's disease, lupus, amyloid lesions, erythema nodosum and primary sclerosing cholangitis, eye diseases, rhinitis and lung inflammation.

[0036] In one embodiment, topical application of R-salbutamol, R-terbutaline and R-clenbuterol can significantly reduce the symptoms of acne, malignant acne, urticaria and eczema. Oral administration of the above drugs to rats can significantly improve psoriasis and eczema.

[0037] The present invention provides new uses of R-salbutamol, R-terbutaline, R-bambuterol and R-clenbuterol in treating inflammatory skin diseases (ISDs) and autoimmune skin diseases associated with IBD, mainly including: psoriasis, rosacea, atopic dermatitis, miliary rash, acne, urticaria, pyoderma gangrenosum, Sweet's syndrome, bowel-associated dermatosis-arthritis syndrome (BADAS), pyodermatitis-purulent stomatitis (PPV). Allergic vasculitis, vitiligo and alopecia areata. Other enantiomer adrenergic β2 agonists have similar pharmacological effects. The present invention discloses uses of other R-enantiomer adrenergic β2 agonists for treating arthritis and other extraintestinal manifestations (EIM) of the above-mentioned IBD. The other chiral β2 agonists according to the present invention include the R or R'R' enantiomers of short-acting β2 agonists: bitolterol, fenoterol, isoproterenol, oxiprol or proterenol-pyridinol, procaterol, ritodrine; and long-acting β2 agonists: aformoterol, formoterol, formoterol fumarate, salmeterol, trobuterol and ultra-long-acting β2 agonists: abedeterol, carmoterol, indolcaterol, oloditerol, vilanterol, isosuprine, mabuterol and zilpaterol.

[0038] The present invention provides a new use of R-enantiomer adrenergic β2 agonist for treating IBD and EIMs of IBD and reducing adverse reactions. The content disclosed in the present invention has never been reported in the prior art and cannot be predicted by those skilled in the art.

[0039] Current treatments for IBD include anti-inflammatory drugs, usually 5-aminosalicylate. This class of drugs includes sulfasalazine, mesalamine, balsalazide, and olsalazide. On the other hand, corticosteroids can be used for moderate to severe ulcerative colitis, including prednisone and hydrocortisone. Other drugs used to treat IBD include immunosuppressive drugs, including azathioprine and mercaptopurine, and less commonly cyclosporine. Antibodies are also used, including infliximab, adalimumab, and golimumab, as well as vedolizumab, certolizumab pegol, natalizumab, ustekinumab, and Bm-ca. However, the above drugs often have serious side effects, and most are not suitable for long-term use. In preclinical and clinical studies, chiral R-enantiomer β2 agonists have shown less toxicity and are relatively safe. The present invention discloses that the combination of R-salbutamol or R-bambuterol or one other R- or R'R' enantiomer β2 agonist and any anti-inflammatory drug (such as 5-aminosalicylate or corticosteroid) has a synergistic effect or allows the dose of the commercially available anti-inflammatory drug to be reduced and the toxicity to be reduced.

[0040] The present invention also discloses that one of R-salbutamol or R-bambuterol or other R- or R'R' enantiomer β2 agonists is combined with any immunosuppressive drug (e.g., thiopurine and mercaptopurine) to have a synergistic effect, or reduce the dose of commercially available immunosuppressive drugs, and reduce the toxicity of the drug. The present invention discloses the combined use of at least one R or R'R-enantiomer β2 agonist and at least one anti-inflammatory drug (including at least one 5-aminoacetic acid and corticosteroid) or at least one of the above immunosuppressants, or at least one of the above immunomodulatory antibodies, or at least one antibiotic to treat IBD and extraintestinal manifestations of IBD.

[0041] Sphingosine-1-phosphate (S1P) receptors are drug targets for IBD. S1P regulates the outflow of lymphocytes from lymph nodes into the circulatory system, which subsequently enhances the inflammatory response in the intestine by producing proinflammatory cytokines. The present invention discloses the combined use of at least one R or R'R-enantiomer β2 agonist and at least one S1P receptor modulator for the treatment of IBD and extraintestinal manifestations of IBD.

[0042] Corticosteroids according to the present invention include budesonide, fluticasone, flunisolide, ciclesonide, mometasone, beclomethasone and dexamethasone.

[0043] The antibiotics involved in the present invention include aminoglycosides, anasemycins, carbacephems, carbapenems, cephalosporins, glycopeptides, lincosamides, lipopeptides, macrolides, monobactams, nitrofurans, oxazolidinones, penicillins, polypeptides, quinolones, sulfonamides, tetracyclines, chloramphenicol, phosphonate antibiotics and mycobacterial antibiotics.

[0044] The antibodies according to the present invention include antibodies to infliximab, adalimumab, golimumab, vedolizumab, certolizumab pegol, natalizumab, ustekinumab and Bm-ca.

[0045] The S1P receptor modulators according to the present invention are fingolimod, ponesimod, siponimod, ozanimod, amisilimod and GSK2018682.

[0046] In an embodiment of the present invention, a new pharmaceutical composition is provided, which contains an effective amount of R-salbutamol or R-bambuterol or other R or R'R-enantiomers and salts thereof of a β2 agonist, for single or combined administration to patients in need thereof by oral administration, oral film, inhalation, nasal spray, injection, topical, eye drops, rectal or vaginal administration. The dosage forms include solid preparations, solutions, aerosols, injections, ointments, skin patches, films, soft capsules and suppositories.

[0047] The enantiomeric ee value or optical purity of the R-enantiomer of the β2 agonist according to the present invention is not less than 80% or preferably greater than 98% or more preferably greater than 99%.

[0048] Pharmaceutically acceptable salts of the R-enantiomer of the β2 agonist according to the present invention include those formed from conventional pharmaceutically acceptable inorganic or organic acids, for example: hydrochloride, hydrobromide, sulfate, hydrogen sulfate, dihydrogen phosphate, methanesulfonate, bromide, methyl sulfate, acetate, oxalate, maleate, fumarate, succinate, 2-naphthalenesulfonate, glycolate, gluconate, citrate, tartrate, lactate, pyruvate isothioate, benzenesulfonate or p-toluenesulfonate. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 .DSS-induced colitis and treatment with RS (R-salbutamol), RB (R-bambuterol), RT (R-terbutaline), RC (R-clenbuterol), SS (S-salbutamol), SB (S-bambuterol), ST (S-terbutaline), RS-C (racemic clenbuterol), and dexamethasone (DEX) for one week.

[0050] Figure 2 .Pathological images of DSS-induced colitis and 2-week treatment with RS, SS, RB, and SB

[0051] Figure 3 Effects of R-salbutamol (R-Sal) and dexamethasone (Dex) on IMQ-induced psoriasis-like back skin lesions after 8 days of treatment.

[0052] Figure 4 .Severity scores of psoriasis areas in IMQ-induced psoriasis-like dorsal lesions after treatment with dexamethasone (Dex), 0.5 mg / kg (R1), 1.0 mg / kg (R2), and 2.0 mg / kg (R3).

[0053] Figure 5 HE staining results of the back skin of mice with IMQ-induced psoriasis treated with salbutamol (R-Sal), bambuterol (R-BMB), and s-salbutamol.

[0054] Figure 6 .The mRNA expression of JAK2 and STAT3 after R-salbutamol treatment.

[0055] Figure 7 .The improvement results of R-salbutamol and indomethacin on inflammatory indicators (bilateral ear thickness and erythema score) of eczema.

[0056] Figure 8Effects of R-salbutamol treatment on histopathology of ear skin in mice with DNCB-induced eczema (400X). (A) Control group; (B) Eczema group: (a) Monocyte infiltration and (b) epidermal keratinization; (C) R-salbutamol (0.05 mg / kg) treatment group: little effect on eczema; (D) R-salbutamol (0.1 mg / kg) treatment group: monocyte infiltration was significantly reduced; (E) R-salbutamol (0.1 mg / kg) treatment group: monocyte infiltration and epidermal keratinization were further reduced; (F) Indomethacin treatment group (5 mg / kg / day).

[0057] Fig. 9 .The therapeutic effect of R-salbutamol on urticaria. Example

[0058] Example 1 Effects of R- and S-enantiomers of β2-agonists on DSS-induced acute colitis

[0059] method

[0060] Animals and drug treatment

[0061] Male C57BL mice (8-10 weeks, 18-20 g) were divided into a control group (drinking water only), a DSS group, and a DSS plus treatment group (n=5). Acute colitis was induced by adding 2% (w / v) dextran sulfate sodium (DSS) with a molecular weight of 36-50 kDa to the drinking water of the mice for 7 days. At the end of the 7th day, DSS was removed and the animals received only drinking water for 2 days. The animals were euthanized on the 10th day after DSS ingestion for anatomical and histological examinations.

[0062] R-Salbuterol (RS) (1 mg / kg), S-Salbuterol (SS) (1 mg / kg), R-Terbutaline (RT) (1 mg / kg), S-Terbutaline (ST) (1 mg / kg), R-Bambuterol (RB) (10 mg / kg), S-Bambuterol (SB) (10 mg / kg), R-Clenbuterol (RC) (1 mg / kg), RS-Clenbuterol (RS-C) (2 mg / kg) were intravenously injected daily for 8 consecutive days starting from the second day of DSS induction. Dexamethasone (Dex) 1 mg / kg was used as a control drug. The enantiomeric ee value of each chiral drug was greater than 98%, and the chemical purity was greater than 99%.

[0063] Evaluation of disease symptoms and histologic changes

[0064] Disease Activity Index (DAI): Animals were monitored daily for body weight, water / food consumption, morbidity, stool consistency, and fecal blood. The disease activity index (DAI) was calculated by combining weight loss, stool consistency, and fecal occult blood, with a range of 0 to 12. The scores were defined as follows: stool consistency was scored as 0 for no diarrhea, 2 for loose stools that did not stick to the anus, and 4 for liquid stools that stuck to the anus; fecal occult blood was scored as 0 for none, 2 for moderate, and 4 for heavy bleeding; weight loss was assigned a value of 0 if the body weight remained at 1% or more of the baseline, 1 for a 1-5% weight loss, 2 for a 5-10% weight loss, 3 for a 10-15% weight loss, and 4 for a weight loss of more than 15%. The length of the colon was recorded as an indicator of inflammation. The entire colon was cut longitudinally and gently rinsed with sterile phosphate-buffered saline (PBS) to remove any traces of feces for pathological examination. The colon segments were fixed in 10% neutral formalin. The tissues were paraffin-embedded, sectioned, and mounted on slides. H&E stained paraffin sections were collected and pathological evaluation was performed in a blinded manner.

[0065] Histological scoring: epithelium, 0 = normal morphology, 1 = goblet cell loss, 2 = extensive goblet cell loss, 3 = crypt loss, 4 = extensive crypt loss; inflammatory cell infiltration, 0 = no infiltration, 1 = pericrypt infiltration, 2 = infiltration into the muscularis mucosa, 3 = extensive infiltration into the muscularis mucosa, mucosal thickening with massive edema, 4 = infiltration of the submucosal layer. Data are expressed as mean ± standard deviation (SD).

[0066] result:

[0067] β2 receptor agonists improve DSS-induced acute colitis.

[0068] Mice orally administered 2% DSS for 7 days developed colitis symptoms, including weight loss, diarrhea, and blood in the stool. The disease activity index (DAI) of DSS mice was significantly increased. Treatment with β2 receptor agonists significantly improved symptoms and reduced DAI values ​​and histological scores. The therapeutic effect of the β2 receptor agonist R-enantiomer was better than that of the control drug dexamethasone (Table 1).

[0069] Table 1. Observation on the efficacy of different treatments for acute DSS colitis

[0070]

[0071] DAI: Disease Activity Index, FOB: Fecal Occult Blood, Col: Colon, Hist: Histology.

[0072] Histological analysis of H&E-stained colon specimens in the control group showed ( Figure 1), the colon mucosal epithelium remained intact and continuous, the crypts were arranged regularly, the structure was clear, and there was no inflammatory cell infiltration and ulceration. In the DSS model group, the mucosa lost its structure, the mucosal epithelium was discontinuous, and extensive ulcerative lesions were formed. The crypts disappeared, the lamina propria was destroyed, the inflammation extended to the mucosa and submucosa, and a large number of inflammatory cells infiltrated. In the R-enantiomer treatment group (DSS+RA or RB or RT or RC), the histological integrity was greatly improved, and the lamina propria was intact. The crypts regenerated, the mucosal epithelium recovered clearly, and the inflammatory infiltration was significantly reduced. In the DSS+DEX treatment group, animals had inflammatory infiltration in the mucosa and submucosa, the lamina propria was destroyed, but there were a small number of incompletely grown crypts and mucosal epithelium. In general, there was some improvement with DSS+DEX treatment, but less improvement compared with R-enantiomer β2 agonist treatment.

[0073] In the S-enantiomer-treated DSS mice (DSS+SS or SB or ST), there was no sign of improvement compared with untreated DSS mice. In contrast, the inflammatory infiltration was more severe in the mucosa, submucosa, and muscularis (DSS+SB), and the lamina propria was completely destroyed (DSS+SS). There were obvious changes in histopathology. The histological scores of S-enantiomer-treated DSS mice were higher than those of untreated DSS mice and much higher than those of R-enantiomer-treated DSS mice.

[0074] When the racemic RS-clenbuterol was used, histological scores were better than those of mice not treated with DSS, but worse than those of mice treated with the R-enantiomer. In DSS mice treated with clenbuterol, the mucosal epithelium disappeared, the lamina propria was destroyed, and there was inflammatory infiltration in the mucosa, submucosa, and muscularis, but with a small amount of crypt regeneration. The overall histology and DAI performance of RS-clenbuterol mice was much less improved than that of DSS mice treated with R-clenbuterol.

[0075] Example 2 Effects of R- and S-enantiomers of β2-agonists on DSS-induced subacute colitis

[0076] method

[0077] Same as Example 1,

[0078] 1) The study period is three weeks, of which the treatment period is one week.

[0079] At the end of the first week, DSS and all treatments were removed and replaced with drinking water. Mice were given free access to water and food for another 2 weeks. Evaluation and examination were performed on day 23 as in Example 1.

[0080] 2) Only R-salbutamol (RS) (1 mg / kg), S-salbutamol (SS) (1 mg / kg),

[0081] R-Bambutrol (RB, 10 mg / kg), S-bambuterol (SB) (10 mg / kg) were used.

[0082] result:

[0083] Effect of R-bambuterol on disease activity index and histological scores.

[0084] In DSS-induced IBD mice, one week after stopping DSS, there was still a significant decrease in body weight and fecal occult blood on days 14 and 22, but it was slightly improved compared with day 7. DAI increased significantly. The disease activity index (DAI) was significantly improved after R-salbutamol treatment compared with untreated DSS animals. The body weight of mice was similar to that of normal controls, and fecal occult blood was significantly reduced after R-salbutamol and R-bambuterol treatment compared with DSS mice. (Table 2)

[0085] In mice with DSS-induced colitis, colon length was significantly shortened and histological scores were significantly higher than those in the control group. There was obvious mononuclear leukocyte infiltration, a small number of newly grown crypts with disordered structures, epithelial exfoliation, mucosal abnormalities, lamina propria destruction, and granuloma formation. Histological indices were also significantly improved after administration of R-salbutamol and R-bambuterol. Mucosal regeneration was complete, crypts were arranged normally, and epithelial growth was normal. The lamina propria was normal. No inflammatory infiltration was observed in the mucosa or submucosal layer.

[0086] Table 2. Observation on the efficacy of different treatments for DSS colitis

[0087]

[0088] DAI: disease active index, FOB: fecal occult blood, Col: Colon, Hist: histological. DAI: disease active index, FOB: fecal occult blood, Col: colon, Hist: histological.

[0089] Example 3 Effect of prolonged treatment in DSS-induced subacute colitis

[0090] method

[0091] 1) Two weeks of treatment in a three-week experimental cycle

[0092] At the end of the first week, the DSS aqueous solution was withdrawn. The drug administration time was started from the first day and continued for 14 days. In the third week, only purified water was drunk. According to the method of Example 1, the mice were killed on the 23rd day and their colons were evaluated and examined. The therapeutic drugs used included R-salbutamol (RS) (1 mg / kg), S-salbutamol (SS) (1 mg / kg), R-bambuterol (RB) (10 mg / kg), and S-bambuterol (SB) (10 mg / kg).

[0093] result:

[0094] Despite some recovery from the disease during the acute phase, the DAI and histological scores of untreated DSS mice were significantly increased. In DSS mice treated with R-salbutamol (DSS+RS) or R-bambuterol (DSS+RB), the DAI and histological scores returned to normal. The mucosa, epithelium, and crypts all appeared normal, and after two weeks of RB or RS treatment, the mucosa, submucosa, and lamina propria were normal with no inflammatory infiltrates ( Figure 2 ,DSS+RB and DSS+RS). In contrast, in DSS mice treated with SS and SB, colitis symptoms were aggravated, and the DAI and histological scores were significantly higher than those in the DSS group. The mucosal epithelium had ulcers and lesions, the crypt structure was disordered, the lamina propria and muscularis mucosa were destroyed, and inflammatory infiltration and abnormal structural state were observed in each layer ( Figure 2 ,DSS+SS,DSS+SB). In general, in DSS-induced chronic colitis, SS and SB treatments led to a severe exacerbation of the disease compared with the model group.

[0095] Example 4 Therapeutic Effect of R-Salbuterol on Psoriasis (Extraintestinal Manifestation of IBD)

[0096] Psoriasis is one of the main extraintestinal manifestations of IBD. Since psoriasis only occurs in a part of IBD mice induced by DSS or TNBS in the present invention, a well-known psoriasis mouse model: IMQ-induced psoriasis-like skin lesions was used for subsequent research.

[0097] method:

[0098] Mice were divided into a control group, a psoriasis group, and a psoriasis plus treatment group (n=8). Imiquimod cream (62.5 mg) was applied to the back skin for 7 consecutive days to induce psoriasis. The control group was treated with an equal amount of petrolatum. Four treatment groups were set up: 3 doses of R-salbutamol (R-Sal) (0.5 mg, 1 mg, 2 mg / kg), and dexamethasone (1 mg / kg) was used as a positive control. The control group was gavaged with an equal amount of normal saline. In some experiments, R-bambuterol (a long-acting β2 agonist) was used as an additional treatment group (n=3). Psoriasis Regional Severity Index was used for evaluation. Each score of erythema, scaling, and skin thickness was measured separately, and then the scores were combined and calculated.

[0099] result:

[0100] (1) Skin manifestations and psoriasis area severity scores

[0101] Imiquimod cream can induce typical psoriasis lesions. The lesions improved significantly after drug treatment ( Figure 3 ). The psoriasis area severity score was the highest in the PSO group. The score was significantly reduced after treatment. There was a dose-dependency for R-salbutamol. High-dose salbutamol (2.0 mg / kg) had the best effect on each score, and its effect was similar to that of dexamethasone (Dex) ( Figure 4 ).

[0102] (2) Histological changes

[0103] Figure 5 Shown are the histological changes after treatment of psoriasis with R-salbutamol, S-salbutamol and R-bambuterol. After IMQ-induced psoriasis, the skin was severely damaged. The lesions were basically recovered after treatment with R-salbutamol and R-bambuterol. It should be noted that after treatment with S-salbutamol, the histological changes of psoriasis worsened, the lesions widened, the epidermis proliferated and thickened (acanthosis), the reticular extension, and the presence of inflammatory infiltration on the epidermis / dermis. The worsening effect of S-salbutamol on psoriasis has never been disclosed in the prior art.

[0104] (3)Signal pathway

[0105] Comparison of plasma from psoriasis mice revealed enhanced mRNA expression of non-receptor tyrosine kinase Janus kinase 2 (JAK2) and signal transducer and activator of transcription (STAT3), suggesting elevated JAK2 and STAT3 proteins. The results showed that R-salbutamol inhibited the overexpression of JAK2 and STAT3 mRNA in a dose-dependent manner ( Figure 6 ).

[0106] The present invention discloses that the therapeutic effect of R-salbutamol R-β2 agonist on psoriasis involves JAK2 and STAT3 signaling pathways, which are also considered to be closely related to the occurrence of IBD diseases. The content disclosed in the present invention is novel and cannot be anticipated by those skilled in the art.

[0107] Example 5 The therapeutic effect of R-salbutamol on eczema (extraintestinal manifestation of IBD)

[0108] Eczema (atopic dermatitis) is one of the main extraintestinal manifestations of IBD. Since only some mice developed eczema in the IBD mice induced by DSS or TNBS in the present invention, a commonly accepted atopic dermatitis mouse model, namely 2,4-dinitrochlorobenzene (DNCB)-induced allergic contact dermatitis, was used in subsequent studies.

[0109] Methods: DNCB-induced allergic contact dermatitis (eczema) model

[0110] The abdominal area of ​​the mice was shaved, and DNCB (100 μL 0.5%) was dissolved and applied to the shaved skin to induce atopic dermatitis for 2 consecutive days. On the 8th day, DNCB was applied to the inner and outer surfaces of the ears to induce eczema. R-salbutamol and indomethacin were administered by gavage from the first day for 8 consecutive days. The mice were dissected on the 9th day and evaluated accordingly.

[0111] Animals and treatment

[0112] The mice were divided into 4 groups (n=8), group A was the control group; group B was the model group (DNCB); group C was the R-salbutamol 0.05, 0.1 or 0.2 mg / kg treatment group; group D was the indomethacin 5 mg / kg treatment group. Inflammation scores were calculated based on bilateral ear swelling, erythema, scratches, thickness, etc.

[0113] Scoring Criteria

[0114]

[0115] result:

[0116] (1) Changes in inflammation scores

[0117] like Figure 7 As shown in the figure, bilateral ear thickness and erythema scores, as inflammatory indicators of eczema, were significantly increased in the model group compared with the control group. After treatment with different doses of R-salbutamol, both thickness and erythema were significantly reduced, while indomethacin had a smaller therapeutic effect.

[0118] (2) Histological changes

[0119] After DNCB modeling, severe eczema can occur. Treatment with R-salbutamol can significantly improve the histological changes of eczema and reduce inflammatory infiltration in a dose-dependent manner. Indomethacin has little effect on eczema ( Figure 8 AF).

[0120] Example 6 Therapeutic Effect of R-Salbuterol on Urticaria (Extraintestinal Manifestation of IBD)

[0121] A healthy female had urticaria on her face and eyelid area for a week. R-salbutamol (R-sal) cream (5%) was applied topically overnight, and the symptoms were significantly relieved the next morning ( Fig. 9 ).

Claims

1. Use of an optically pure R-enantiomer of a selective β2 adrenergic receptor agonist in the preparation of a pharmaceutical preparation for treating inflammatory bowel disease in humans or animals, wherein the preparation uses any one of terbutaline, bambuterol and clenbuterol as an active ingredient.

2. The use according to claim 1, characterized in that The S-enantiomers of terbutaline, bambuterol and clenbuterol have toxicity that exacerbates inflammatory bowel disease.

3. The use according to claim 1, characterized in that The inflammatory bowel disease is inflammatory hemorrhoids.

4. The use according to claim 1, characterized in that The preparation is in the form of a solid dosage form or a solution dosage form.

5. The use according to claim 1, characterized in that The preparation is a spray, a skin patch, or an intestinal suppository.

Citation Information

Patent Citations

  • Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation

    US20090263454A1